세계의 여성 건강 기기 시장은 2025년에 603억 9,000만 달러로 평가되었고, 2026년 658억 9,000만 달러에서 2034년까지 1,415억 7,000만 달러로 성장할 전망이며, 예측 기간(2026-2034년) CAGR 10.03%를 기록할 것으로 예측되고 있습니다. 2025년에는 북미가 45.70%의 점유율로 시장을 선도했으며, 이는 의료 지출의 견조함, 여성 질환의 높은 유병률, 기술적으로 고급 의료기기에 대한 수요 증가가 주요 요인입니다.
여성 건강(여성의 건강 문제)에 대한 의식이 높아지고, 가처분 소득 증가, 유방암이나 난소암 등 여성 특유의 암이나 자궁근종 등의 질환 증가가 시장 성장을 견인하는 주요 요인입니다. 게다가 젊은 세대의 여성들이 선진적인 건강 모니터링 및 진단 기기를 적극적으로 채용하는 경향이 강해지고 있어 시장 전체의 확대를 뒷받침하고 있습니다.
시장 개요
여성 건강 분야의 최근 동향을 통해 기업은 연구 개발 및 진단 및 모니터링 장비에서 치료 장비에 이르기까지 신제품 출시에 많은 투자를 할 수 있습니다. 예를 들어, 2021년 12월 F. Hofman La Roche는 진행성 또는 전이성 유방암을 위한 cobas PIK3CA 돌연변이 검사를 시작하고 치료의 정확성을 높이며 장비 채용을 추진하고 있습니다.
COVID-19 팬데믹으로 인해 병원 통원이 제한되어 공급망이 혼란스러워 시장 성장이 일시적으로 정체되었습니다. 예를 들어 쿠퍼 서지컬은 2020년 불임 치료 부문의 수익이 11.2% 감소했다고 보고했습니다. 그러나 2021년에는 원격 의료 및 원격 환자 케어 솔루션의 채용 증가에 힘입어 시장은 39.2%의 매출 성장률로 회복되었습니다.
시장 성장 촉진요인
여성 건강 문제에 대한 의식 증가
의료 인프라의 정비와 미국 식품의약국(FDA)의 '여성의 건강 프로그램' 등의 조직에 의한 계발 캠페인에 의해 조기 발견과 예방 의료를 위한 의료기기의 채용이 대폭 증가하고 있습니다. 이러한 노력은 특히 젊은 여성들에게 큰 영향력을 가지고 있으며 진단, 치료 및 모니터링 장비에 대한 수요가 증가하고 있습니다.
여성 질환 증가 경향
자궁경부암, 유방암, 자궁근종 등 여성 특유의 암이나 만성질환의 이환율 증가에 따라 전문의료기기에 대한 수요가 높아지고 있습니다. WHO 2022년 보고에 따르면 자궁경부암은 여성의 암 발생률 4위이며, 2020년에는 60만 4천 건의 신규 증례가 보고되었습니다. 이러한 동향이 연구개발 및 제품 투입을 촉진하여 시장 성장을 더욱 뒷받침하고 있습니다.
시장 성장 억제요인
신흥 지역의 낮은 인지도와 의료 보급률이 시장 성장을 제한하고 있습니다. 인도나 사하라 이남 아프리카 등의 국가에서는 문화적 금기, 진단 의식이 낮고, 선진 기기에 대한 액세스 제한으로 인해 여성 건강 기술의 활용이 불충분하여 시장 전체의 확대를 억제하고 있습니다.
The global women's health devices market was valued at USD 60.39 billion in 2025 and is projected to grow from USD 65.89 billion in 2026 to USD 141.57 billion by 2034, registering a CAGR of 10.03% during the forecast period (2026-2034). North America dominated the market in 2025 with a 45.70% share, driven by strong healthcare expenditure, a high prevalence of female diseases, and growing demand for technologically advanced medical devices.
Rising awareness of female health issues, increased disposable incomes, and the growing prevalence of female cancers, such as breast and ovarian cancers, and other conditions like uterine fibroids are major factors driving market growth. Additionally, younger generations of women are increasingly adopting advanced health monitoring and diagnostic devices, boosting overall market expansion.
MARKET OVERVIEW
Recent developments in the women's health space have motivated companies to invest heavily in R&D and new product launches, ranging from diagnostic and monitoring devices to therapeutic equipment. For example, in December 2021, F. Hoffmann-La Roche Ltd launched the cobas PIK3CA Mutation Test for advanced or metastatic breast cancer, enhancing treatment precision and driving device adoption.
The COVID-19 pandemic temporarily hindered market growth due to limited hospital visits and disrupted supply chains. CooperSurgical Inc., for instance, reported an 11.2% revenue decline in 2020 in its fertility segment. However, by 2021, the market rebounded with 39.2% sales growth, aided by the increasing adoption of telemedicine and remote patient care solutions.
MARKET DRIVERS
Increasing Awareness of Women's Health Issues
Enhanced healthcare infrastructure, coupled with awareness campaigns by organizations like the U.S. FDA's Health of Women Program, has significantly increased women's adoption of health devices for early detection and preventive care. These initiatives have been particularly influential among younger women, leading to greater demand for diagnostic, therapeutic, and monitoring devices.
Rising Prevalence of Female Diseases
The growing prevalence of female cancers and chronic conditions such as cervical cancer, breast cancer, and uterine fibroids has escalated demand for specialized medical devices. According to WHO 2022, cervical cancer is the 4th most common cancer among women, with 604,000 new cases reported in 2020. Such trends are driving R&D initiatives and product launches, further propelling market growth.
RESTRAINING FACTORS
Limited awareness and low healthcare penetration in emerging regions restrict market growth. In countries like India and sub-Saharan Africa, cultural taboos, low diagnostic awareness, and limited access to advanced devices result in underutilization of women's health technologies, restraining overall market expansion.
SEGMENTATION
By Application
The cancers & other chronic diseases segment accounted for 34.74% of the market in 2026, due to high demand for effective diagnostic and therapeutic devices. The pregnancy & nursing care segment and reproductive health segment follow, driven by adoption of pregnancy diagnostics, breast pumps, and contraceptive devices. Pelvic and uterine healthcare devices, including urinary incontinence solutions, are also witnessing strong growth.
By End-User
Hospitals and clinics dominated the market in 2026 with a 59.42% share, due to patient influx for diagnostic and therapeutic treatments. Home healthcare is growing fastest, as patients increasingly prefer convenient at-home monitoring solutions. The "others" segment, which includes specialized clinics and telemedicine services, is growing steadily.
REGIONAL INSIGHTS
North America led the market with USD 27.60 billion in 2025, supported by strong government initiatives, technological adoption, and healthcare investments. Europe followed, with Germany and the U.K. expected to reach USD 4.48 billion and USD 2.85 billion by 2026, respectively, driven by high prevalence of female cancers and robust healthcare infrastructure.
Asia Pacific is projected to register the strongest CAGR due to increasing awareness, improved healthcare infrastructure, and approvals for advanced devices. Japan, China, and India are expected to reach USD 3.87 billion, USD 4.68 billion, and USD 2.2 billion by 2026, respectively. Emerging regions, including Latin America and the Middle East & Africa, are experiencing moderate growth due to improving healthcare access and increasing awareness.
KEY INDUSTRY PLAYERS
Prominent players include F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, CooperSurgical Inc., Hologic Inc., Coloplast A/S, and ALLERGAN (AbbVie, Inc.). These companies are strengthening their portfolios through R&D, acquisitions, and strategic partnerships. For instance, CooperSurgical acquired Cook Medical's reproductive health portfolio for USD 875 million in 2022, expanding offerings in fertility, obstetrics, and gynecology devices.
CONCLUSION
The global women's health devices market is poised for robust growth from USD 60.39 billion in 2025 to USD 141.57 billion by 2034, driven by increasing prevalence of female diseases, awareness campaigns, technological advancements, and home healthcare adoption. Despite challenges in emerging markets, strategic investments, R&D innovations, and government initiatives are expected to sustain market expansion, making the sector highly attractive for global players and new entrants alike.
Segmentation By Application, End-user, and Region
By Application * General Health & Wellness
By End-user * Hospitals & Clinics
By Region * North America (By Application, By End-user, and By Country)